A better understanding of why some people are predisposed to dangerous drug interactions and serious illness when taking new prescriptions will be the charge of a non-profit group being formed by several of the world's largest pharmaceutical companies and the federal government. 

Called the International Serious Adverse Event Consortium, the group will be announced Thursday by the Food and Drug Administration and seven drug making founders of the organization that include North Chicago-based Abbott Laboratories, Johnson & Johnson and Pfizer Inc. The new group's office will be based in north suburban Deerfield.

Drug companies and the FDA alike have been under fire for perceived lax monitoring of prescription drugs once they reach the market. This was heightened three years ago this Sunday when Merck & Co. pulled Vioxx from the market after a study showed the drug, which had been on the market for more than four years, was associated with an increased risk of heart attacks and strokes.

Drug companies, which have large databases of reports from patients and doctors on how their drugs interact with patients, say they will use their information to conduct studies that will provide a map of "genetic markers" linked to serious adverse events, or SAEs, which can lead to serious injuries or death. Databases from universities and other consortia will also be used.

But because new medications such as expensive genetically-engineered drugs are complicated and costly to develop, these companies and their academic partners in the consortium cannot tackle the issue on their own.

"Patient safety is one of the biggest priorities of the FDA, and we are encouraged by this new consortium that will accelerate and advance our understanding of genetic variants associated with serious drug-related adverse events," said Dr. Janet Woodcock, the FDA's deputy commissioner and chief medical officer. "Given the considerable size and cost of conducting safety studies, a coordinated strategic partnership between industry, academia and government can more rapidly advance this critical science."

The group hopes to reduce an estimated 150,000 deaths and annual costs of more than $100 billion to the U.S. economy from serious adverse events by addressing more safety issues for drugs before they reach the market.

Its first two studies will look at drug-related liver toxicity and Stevens-Johnson syndrome, a severe skin problem that leads to blisters, among other health problems.

"The traditional research model only provides one piece of the puzzle in understanding the genetic variations that could lead to an increased risk of an adverse event," said the consortium's chairman and chief executive, Arthur Holden, formerly an executive at diagnostic-test maker Illumina Inc. "The most efficient way to study drug-induced SAEs is to create a global, publicly available 'knowledge base' that will help identify the genetic variations that may predict SAEs."



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

Levetiracetam linked to serious and life-threatening...

Gustav was on the anti-seizure medication Keppra for a year when his insurance company switched him to...

Dangerous skin reactions from Carbamazepine

A March 2008 FDA patient safety news bulletin reiterated warnings to healthcare professionals about...

Stevens Johnson Syndrome a Rare Skin Disorder

Stevens-Johnson syndrome is a rare, serious disorder of the skin and mucous membranes. It begins with...

FDA Issues an FDA Alert for Fatal Skin Reactions...

Dangerous or even fatal skin reactions (Stevens Johnson syndrome and toxic epidermal necrolysis), that...

FDA Warns of HLA Allele Linked to Skin Reaction with...

Stevens Johnson syndrome or related toxic epidermal necrolysis may be caused by carbamazepine therapy,...

Warnings Added to Prescribing Information

Updates safety information to include warnings regarding serious rash, including Stevens-Johnson...

Wonderful to work with

Beasley Allen did a great job with my case. They were wonderful to work with. They were available by phone when I needed them, treated me with the utmost respect and worked hard on my behalf. If a need arises in the future, I would definitely call on them again.

—Geraldine